A Web-based Platform to Share Harmonized Results from COVID-19 Clinical Studies.

Irena Parvanova, Kirill Borziak, Anar Poltinnikov, Joseph Finkelstein

Abstract read

In one paragraph

Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Towards an Open-Source Platform to Harmonize and Share Research Results from COVID-19 Interventional and Observational Studies.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Irena ParvanovaIcahn School of Medicine at Mount Sinai, New York, New York, USA.

Kirill BorziakIcahn School of Medicine at Mount Sinai, New York, New York, USA.

Anar PoltinnikovIcahn School of Medicine at Mount Sinai, New York, New York, USA.

Joseph FinkelsteinIcahn School of Medicine at Mount Sinai, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 has caused a worldwide pandemic, accompanied by a high number of deaths and hospitalizations. Multiple preventative vaccines and variety of COVID-19 treatments have been developed and explored. This large volume of scientific work led to an extensive number of COVID-19 publications, which resulted in the necessity to standardize, store, share, and investigate research results in a harmonized manner. Attempts to standardize and share COVID-19 research data have been lacking. The purpose of the ReMeDy platform is to provide an intelligent informatics solution of integrating diverse COVID-19 trial outcomes and omics data across COVID-19 research studies. To test the platform, we utilized 48 COVID-19 observational retrospective studies. The robustness of the platform was validated through the ability to efficiently organize the diverse data elements. Next steps include expanding our database through the inclusion of all published COVID-19 studies. ReMeDy is located at https://remedy.mssm.edu/.

Indexed as

COVID-19HumansInternetPandemicsRetrospective Studies

Identifiers

PMID37128442

PMCPMC10148277

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.